Tired of Gluten-Free Foods? Watch This Pipeline Drug!
In the following video, Fool contributor Maxx Chatsko has some great news for individuals with celiac disease, also known as gluten allergies. AbbVie recently entered into an exclusive deal with Alvine Pharmaceuticals centered around a novel treatment for celiac disease. The therapy consists of two recombinant, gluten-specific enzymes that break down gluten in the body and have been shown to reduce inflammation in early and mid-stage trials.
It may be early, but if the current phase 2b trial succeeds, AbbVie investors have the right to be excited: There are currently no treatments approved for celiac disease -- a massive market. Therefore, I would rather see AbbVie acquire Alvine than just the drug in question, since the small company has several therapies in early development for celiac disease. Could this be just the opportunity the company needs to cushion the impending fall of Humira? Get more details in the video below.
In the pharma business, great success comes with a caveat. AbbVie is a perfect example, as investors in the new company are left wondering what the future holds once the company's golden goose, Humira, is cooked. The Fool's brand new premium report on the company answers the high-profile questions that AbbVie investors are asking. Simply click here now to claim your copy today.
The article Tired of Gluten-Free Foods? Watch This Pipeline Drug! originally appeared on Fool.com.Fool contributor Maxx Chatsko has no position in any stocks mentioned. Check out his personal portfolio, his CAPS page, or follow him on Twitter @BlacknGoldFool to keep up with his writing on energy, bioprocessing, and emerging technologies. The Motley Fool recommends Johnson & Johnson. The Motley Fool owns shares of Johnson & Johnson. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.